Corcept Therapeutics Inc..
Corcept Therapeutics, a US biotech, markets Korlym for Cushing’s‑associated hyperglycemia and leads phase‑III programs relacorilant (Cushing’s & ovarian cancer), nab‑paclitaxel combo and prostate therapy.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 500
- HQ: Redwood City
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.